Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EWEBNASDAQ:NZUSNASDAQ:VRNASDAQ:XDNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEWEBGlobal X Emerging Markets Internet & E-commerce ETF$21.14$21.14$18.42▼$25.54$2.54M0.42469 shsN/ANZUSSPDR MSCI USA Climate Paris Aligned ETF$31.56+2.1%$29.31$26.06▼$34.03$2.52M-1.1811 shs184 shsVRGlobal X Metaverse ETF$25.61$25.60$20.38▼$26.36$2.56M-1.521,191 shsN/AXDNAKelly CRISPR & Gene Editing Technology ETF$7.38$7.38$5.87▼$11.83$2.21M0.923,034 shsN/A7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEWEBGlobal X Emerging Markets Internet & E-commerce ETF0.00%0.00%0.00%0.00%0.00%NZUSSPDR MSCI USA Climate Paris Aligned ETF0.00%-2.85%+6.54%-3.04%+3.94%VRGlobal X Metaverse ETF0.00%0.00%0.00%0.00%0.00%XDNAKelly CRISPR & Gene Editing Technology ETF0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEWEBGlobal X Emerging Markets Internet & E-commerce ETFN/AN/AN/AN/AN/AN/AN/AN/ANZUSSPDR MSCI USA Climate Paris Aligned ETFN/AN/AN/AN/AN/AN/AN/AN/AVRGlobal X Metaverse ETFN/AN/AN/AN/AN/AN/AN/AN/AXDNAKelly CRISPR & Gene Editing Technology ETFN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEWEBGlobal X Emerging Markets Internet & E-commerce ETF 2.74Moderate Buy$21.14N/ANZUSSPDR MSCI USA Climate Paris Aligned ETF 2.74Moderate Buy$31.56N/AVRGlobal X Metaverse ETF 2.72Moderate Buy$25.61N/AXDNAKelly CRISPR & Gene Editing Technology ETF 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEWEBGlobal X Emerging Markets Internet & E-commerce ETFN/AN/AN/AN/AN/AN/ANZUSSPDR MSCI USA Climate Paris Aligned ETFN/AN/AN/AN/AN/AN/AVRGlobal X Metaverse ETFN/AN/AN/AN/AN/AN/AXDNAKelly CRISPR & Gene Editing Technology ETFN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEWEBGlobal X Emerging Markets Internet & E-commerce ETFN/AN/A25.72∞N/AN/AN/AN/AN/ANZUSSPDR MSCI USA Climate Paris Aligned ETFN/AN/A29.45∞N/AN/AN/AN/AN/AVRGlobal X Metaverse ETFN/A-$2.08N/A∞N/AN/AN/AN/AN/AXDNAKelly CRISPR & Gene Editing Technology ETFN/AN/A17.02∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEWEBGlobal X Emerging Markets Internet & E-commerce ETF$0.060.28%N/AN/AN/ANZUSSPDR MSCI USA Climate Paris Aligned ETF$1.785.64%N/AN/AN/AVRGlobal X Metaverse ETF$1.636.36%N/AN/A N/AXDNAKelly CRISPR & Gene Editing Technology ETFN/A0.12%N/AN/AN/ALatest VR, XDNA, EWEB, and NZUS DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date2/28/2025NZUSSPDR MSCI USA Climate Paris Aligned ETF$0.05183/3/20253/3/20253/5/2025(Data available from 1/1/2013 forward)Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEWEBGlobal X Emerging Markets Internet & E-commerce ETFN/ANZUSSPDR MSCI USA Climate Paris Aligned ETFN/AVRGlobal X Metaverse ETF81.98%XDNAKelly CRISPR & Gene Editing Technology ETFN/AInsider OwnershipCompanyInsider OwnershipEWEBGlobal X Emerging Markets Internet & E-commerce ETFN/ANZUSSPDR MSCI USA Climate Paris Aligned ETFN/AVRGlobal X Metaverse ETF2.33%XDNAKelly CRISPR & Gene Editing Technology ETFN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEWEBGlobal X Emerging Markets Internet & E-commerce ETFN/A120,000N/ANo DataNZUSSPDR MSCI USA Climate Paris Aligned ETFN/A80,000N/AOptionableVRGlobal X Metaverse ETFN/A100,000N/AOptionableXDNAKelly CRISPR & Gene Editing Technology ETFN/A300,000N/AOptionableVR, XDNA, EWEB, and NZUS HeadlinesRecent News About These CompaniesCHOP, Penn advance CRISPR gene editing with fast-developed treatment for an infant with a rare diseaseMay 15, 2025 | msn.comNobel Prize winners convince court to revive CRISPR patent disputeMay 12, 2025 | reuters.comBiotech investors: Stop expecting CRISPR science to make big leapsApril 14, 2025 | statnews.comAI and gene editing promise ‘bespoke proteins’ for biotechOctober 8, 2024 | siliconrepublic.comWeight loss drug breakthroughs, gene therapies, and more: 8 clinical trials to watch right nowOctober 2, 2024 | yahoo.comK-12 Genome Editing at Only $2 a PopSeptember 27, 2024 | yahoo.comVertex Stock: Came For CF Drugs, Staying For Gene TherapyAugust 2, 2024 | seekingalpha.comCRISPR can treat common form of inherited blindness, early data hintMay 15, 2024 | msn.comCRISPR gene editing: in summaryMarch 27, 2024 | biotechniques.comCRISPR Technology Takes Center Stage at SXSW 2024 for the First TimeMarch 9, 2024 | markets.businessinsider.comIntellia Collaborates With ReCode To Develop Gene Therapy For Cystic FibrosisFebruary 15, 2024 | markets.businessinsider.comCRISPR Technology: Unveiling the Breakthrough in Gene Editing and Its Far-Reaching ImplicationsJanuary 18, 2024 | techbullion.comHere's Why CRISPR Therapeutics Stock Rose 54% Last YearJanuary 15, 2024 | msn.comGene editing is now a medical realityDecember 8, 2023 | news.yahoo.comFDA approves first use of CRISPR gene editing to treat sickle cell diseaseDecember 8, 2023 | news.yahoo.comFDA Approves First Gene-Editing Cell Therapy For Sickle Cell Disease, An Inherited Blood DisorderDecember 8, 2023 | markets.businessinsider.comGene Editing Will Change Medicine—and Maybe Health Investing TooNovember 24, 2023 | msn.comCRISPR/Cas9 unlocks TuMV resistance in Chinese cabbage: A leap forward in genome-edited plant breedingNovember 24, 2023 | phys.orgIs CRISPR Therapeutics the Best Gene-Editing Stock?November 22, 2023 | msn.comThree people were gene-edited in an effort to cure their HIV. The result is unknown.November 16, 2023 | technologyreview.comMedia Sentiment Over TimeTop HeadlinesView All HeadlinesQualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongWhy D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumSuper Micro Computer Stock Clears New Path Higher on Saudi OrdersBy Gabriel Osorio-Mazilli | May 22, 2025View Super Micro Computer Stock Clears New Path Higher on Saudi OrdersBP Buyout Buzz Puts Spotlight on Transocean’s Comeback PotentialBy Gabriel Osorio-Mazilli | May 12, 2025View BP Buyout Buzz Puts Spotlight on Transocean’s Comeback PotentialChevron’s Fundamentals Shine Through Market TurmoilBy Chris Markoch | May 6, 2025View Chevron’s Fundamentals Shine Through Market TurmoilVR, XDNA, EWEB, and NZUS Company DescriptionsGlobal X Emerging Markets Internet & E-commerce ETF NASDAQ:EWEB$21.14 0.00 (0.00%) As of 05/23/2025The Global X Emerging Markets Internet & E-commerce ETF (EWEB) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund tracks an index of companies positioned to benefit from the advancement of internet and e-commerce technologies in emerging market countries. EWEB was launched on Nov 9, 2020 and is managed by Global X.SPDR MSCI USA Climate Paris Aligned ETF NASDAQ:NZUS$31.56 +0.66 (+2.12%) As of 01:24 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.The SPDR MSCI USA Climate Paris Aligned ETF (NZUS) is an exchange-traded fund that is based on the MSCI USA Climate Paris Aligned index. The fund tracks a tier-weighted index of large- and mid-cap US stocks selected and weighted based on ESG criteria that are compatible with the Paris Climate Agreement and carbon reduction goals. NZUS was launched on Apr 21, 2022 and is managed by State Street.Global X Metaverse ETF NASDAQ:VRThe Global X Metaverse ETF (VR) is an exchange-traded fund that is based on the Global X Metaverse index. The fund tracks a market cap-weighted index of 40 global companies that derive revenue from or have primary business operations associated with the Metaverse. VR was launched on Apr 26, 2022 and is managed by Global X.Kelly CRISPR & Gene Editing Technology ETF NASDAQ:XDNA$7.38 0.00 (0.00%) As of 05/23/2025The Strategic CRISPR & Gene Editing Technology ETF (XDNA) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a market-cap-weighted index of companies in developed markets that focus on the advancements in DNA modification technology. XDNA was launched on Jan 12, 2022 and is managed by Kelly. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Scores First $1 Billion Contract; Is It Priced In? Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings Navitas Soars on NVIDIA Deal: Breaking Down its Tech and Outlook MarketBeat Week in Review – 05/19 - 05/23 Workday Stock Price Implosion: An Automatic Buy for AI Investors Can Ross Stores Be the Safety Cushion In Retail Stocks? MercadoLibre Is Soaring—Should You Wait for a Better Entry? Trade Desk Silences Critics; Recovery Looks Poised to Continue Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
